FIELD: biotechnology.
SUBSTANCE: group of inventions relates to antagonists of a receptor of αvβ3 thyroid integrin hormone, conjugated with targets of a norepinephrine transporter (NET) or a catecholamine transporter. A compound is disclosed, containing N-benzylguanidine and an antagonist of αvβ3 thyro-integrin receptor, where N-benzylguanidine and the antagonist of αvβ3 thyro-integrin receptor are connected by a linker. A specific case of the specified compound, a compound for double targeting to tumor cells, and a method for double targeting to tumor cells are also disclosed.
EFFECT: group of inventions provides increased efficiency of targeting in the treatment and diagnostic imaging of neuro-endocrine tumors.
19 cl, 13 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID DELIVERY SYSTEM | 2002 |
|
RU2294192C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| METHODS FOR TREATMENT OF TUMORS AND METASTASIS USING COMBINATION OF ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY | 2000 |
|
RU2236251C2 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
